Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity

Clinical Endocrinology

Volumn 63, Issue 5, 2005, Pages 594-598

  Kim, S M ^a   Leet, J ^a   Ryu, O H ^a   Lee, K W ^a   Kim, H Y ^a   Seo, J A ^a   Kim, S G ^a   Kim, N H ^a   Baik, S H ^a   Choi, D S ^a   Choi, Kyung Mook ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 6; LIPID; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ADULT; ANKLE; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RIGIDITY; SYSTEMIC DISEASE; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; GLYCOPROTEINS; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PULSATILE FLOW; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SIGNAL PROCESSING, COMPUTER-ASSISTED; SYSTOLE; TRIGLYCERIDES;

EID: 27744564963     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02390.x     Document Type: Article

References (29)

1. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. & Boyle, W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-319.
2. Malyankar, U.M., Scatena, M., Suchland, K.L., Yun, T.J., Clark, E.A. & Giachelli, C.M. (2000) Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. Journal of Biological Chemistry, 275, 20959-20962.
3. Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H.L., Xu, W., Lacey, D.L., Boyle, W.J. & Simonet, W.S. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development, 12, 1260-1268.
4. Min, H., Morony, S., Sarosi, I., Dunstan, C.R., Capparelli, C., Van Scully, S.G., Kaufman, S., Kostenuik, P.J., Lacey, D.L., Boyle, W.J. & Simonet, W.S. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. Journal of Experimental Medicine, 192, 463-474.
5. Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K. & Nishizawa, Y. (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 106, 1192-1194.
6. Schoppet, M., Sattler, A.M., Schaefer, J.R., Herzum, M., Maisch, B. & Hofbauer, L.C. (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism, 88, 1024-1028.
7. Browner, W.S., Lui, L.Y. & Cummings, S.R. (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism, 86, 631-637.
8. Schoppet, M., Preissner, K.T. & Hofbauer, L.C. (2002) RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 549-553.
9. Paoletti, R., Gotto, A.M. Jr & Hajjar, D.P. (2004) Inflammation in atherosclerosis and implications for therapy. Circulation, 109, III20-III26.
10. Willerson, J.T. & Ridker, P.M. (2004) Inflammation as a cardiovascular risk factor. Circulation, 109, II2-II10.
11. American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care, 28, S37-S42.
12. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
13. Choi, K.M., Lee, K.W., Seo, J.A., Oh, J.H., Kim, S.G., Kim, N.H., Choi, D.S. & Baik, S.H. (2004) Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. Diabetes Research and Clinical Practice, 66, 57-61.
14. Sattler, A.M., Schoppet, M., Schaefer, J.R. & Hofbauer, L.C. (2004) Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcified Tissue International, 74, 103-106.
15. Emery, J.G., McDonnell, P., Burke, M.B., Deen, K.C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E.R., Eichman, C., DiPrinzio, R., Dodds, R.A., James, I.E., Rosenberg, M., Lee, J.C. & Young, P.R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry, 273, 14363-14367.
16. Kiechl, S., Schett, G., Wenning, G., Redlich, K., Oberhollenzer, M., Mayr, A., Santer, P., Smolen, J., Poewe, W. & Willeit, J. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109, 2175-2180.
17. Price, P.A., June, H.H., Buckley, J.R. & Williamson, M.K. (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 1610-1616.
18. Ueland, T., Jemtland, R., Godang, K., Kjekshus, J., Hognestad, A., Omland, T., Squire, I.B., Gullestad, L., Bollerslev, J., Dickstein, K. & Aukrust, P. (2004) Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology, 44: 1970-1976.
19. Hofbauer, L.C. & Schoppet, M. (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet, 358, 257-259.
20. Ugur-Altun, B., Altun, A., Gerenli, M. & Tugrul, A. (2005) The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Research and Clinical Practice, 68, 217-222.
21. Knudsen, S.T., Foss, C.H., Poulsen, P.L., Andersen, N.H., Mogensen, C.E. & Rasmussen, L.M. (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. European Journal of Endocrinology, 149, 39-42.
22. Olesen, P., Ledet, T. & Rasmussen, L.M. (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia, 48, 561-568.
23. Rhee, E.J., Lee, W.Y., Kim, S.Y., Kim, B.J., Sung, K.C., Kim, B.S., Kang, J.H., Oh, K.W., Oh, E.S., Baek, K.H., Kang, M.I., Woo, H.Y., Park, H.S., Kim, S.W., Lee, M.H. & Park, J.R. (2005) Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clinical Science, 108, 237-243.
24. Yudkin, J.S., Kumari, M., Humphries, S.E. & Mohamed-Ali, V. (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 148, 209-214.
25. Collin-Osdoby, P. (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research, 95, 1046-1057.
26. Rasmussen, L.M. & Ledet, T. (2005) Osteoprotegerin and diabetic macroangiopathy. Hormone and Metabolic Research, 37, 90-94.
27. Suzuki, K., Kurose, T., Takizawa, M., Maruyama, M., Ushikawa, K., Kikuyama, M., Sugimoto, C., Seino, Y., Nagamatsu, S. & Ishida, H. (2005) Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Research and Clinical Practice, 68, 117-125.
28. Meaume, S., Benetos, A., Henry, O.F., Rudnichi, A. & Safar, M.E. (2001) Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2046-2050.
29. Shoji, T., Emoto, M., Shinohara, K., Kakiya, R., Tsujimoto, Y., Kishimoto, H., Ishimura, E., Tabata, T. & Nishizawa, Y. (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. Journal of the American Society of Nephrology, 12, 2117-2124.